Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $27.18 and last traded at $26.82, with a volume of 1315 shares traded. The stock had previously closed at $25.22.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. assumed coverage on Ascentage Pharma Group International in a report on Thursday, March 27th. They set an "overweight" rating for the company.
View Our Latest Stock Report on AAPG
Ascentage Pharma Group International Price Performance
The company has a fifty day moving average of $23.35.
Institutional Investors Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new stake in Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Featured Stories
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
